Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities
But Studies Going Strong
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
